*Rule 3.19A.2*

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

| | |
|---|---|
| **Name of entity** | **PYC THERAPEUTICS LIMITED** |
| **ABN** | **48098391961** |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|---|---|
| **Name of Director** | Dr Rohan Hockings |
| **Date of last notice** | 14 August 2026 |

**Part 1 - Change of director's relevant interests in securities**
*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Direct or indirect interest** | Direct |
| **Nature of indirect interest (including registered holder)**<br>Note: Provide details of the circumstances giving rise to the relevant interest. | N/A |
| **Date of change** | 3 November 2026 |
| **No. of securities held prior to change** | 295,910 – Ordinary fully paid<br>7,706,503 Unquoted Options EXP 30 June 27 EX $1.68<br>4,598,662 Unquoted Options EXP 30 June 28 EX $1.68<br>10,477,965 Unquoted Options EXP 30 June 28 EX $1.68 |
| **Class** | PYC: Ordinary fully paid |
| **Number acquired** | 115,000 |
| **Number disposed** | NIL |
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and estimated valuation | $206,423.83 ($1.79499 per share) |

+ See chapter 19 for defined terms.

| | |
|---|---|
| **No. of securities held after change** | 410,910 – Ordinary fully paid<br>7,706,503 Unquoted Options EXP 30 June 27 EX $1.68<br>4,598,662 Unquoted Options EXP 30 June 28 EX $1.68<br>10,477,965 Unquoted Options EXP 30 June 28 EX $1.68 |
| **Nature of change**<br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | On-market acquisition |

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Detail of contract** | 13 January 2026 – Offer Invitation under the terms of the Company's Long Term Incentive Plan (existing contract 1)<br>13 August 2026 -Offer Invitation under the terms of the Company's Limited Rights Plan (new contract 2) |
| **Nature of interest** | Contract 1 - Subject to shareholder approval. To be issued 1,500,000 unlisted options exercisable by payment of $2.52 each on or before the date that is 48 months from the date of issue. Fifty percent of the options will vest 12 months from the date of issue and fifty percent will vest 24 months from the date of issue.<br><br>Contract 2 - Subject to shareholder approval at the Company's 2026 Annual General Meeting. To be granted 289,855 Restricted Rights under the PYC Therapeutics Limited Rights Plan. The Rights are fully vested on grant but are subject to an Exercise Restriction Period ending 30 June 2028. Each Right has a nil exercise price and may be settled in Shares or cash (or a combination), at the discretion of the Board, in accordance with the Rules of the Plan |
| **Name of registered holder (if issued securities)** | N/A |
| **Date of change** | N/A |
| **No. and class of securities to which interest related prior to change**<br>Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| **Interest acquired** | N/A |

+ See chapter 19 for defined terms.

| | |
|---|---|
| **Interest disposed** | N/A |
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| **Interest after change** | N/A |

## Part 3 – +Closed period

| | |
|---|---|
| **Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?** | NO |
| **If so, was prior written clearance provided to allow the trade to proceed during this period?** | N/A |
| **If prior written clearance was provided, on what date was this provided?** | N/A |

+ See chapter 19 for defined terms.